Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/10/2025

Tapering Benzodiazepines in Long-Term Users

Introduction to Tapering

  • The American Academy of Family Physicians and other guideline societies recommend tapering benzodiazepines over 12-24 months in patients who have been taking them for 15 years, with a very slow taper reducing by 10% of the current dose per month, which translates to approximately 2mg reductions monthly initially, slowing further as you approach lower doses 1, 2, 3

Critical Safety Considerations

  • The Mayo Clinic guidelines emphasize that withdrawal should often be more gradual than the commonly suggested 25% weekly reduction, particularly considering the patient's treatment duration, to avoid seizures and death 1, 2
  • Longer duration of benzodiazepine therapy requires longer tapers—patients on benzodiazepines for ≥1 year need tapers extending over several months to years, with the Centers for Disease Control and Prevention (CDC) recommending a gradual taper 4, 5
  • The Mayo Clinic guidelines recommend starting with 10% monthly reductions of the current dose, with the taper slowing down as doses decrease, and considering reducing by only 5-10% every 4-6 weeks as withdrawal symptoms may intensify at lower doses 1, 2, 3, 6
  • When reaching doses below 5mg daily, consider even slower reductions of 0.25-0.5mg every 2-4 weeks, as recommended by the American Academy of Family Physicians 3, 5

Managing Withdrawal Symptoms

  • Consider gabapentin 100-300mg at bedtime or three times daily, increasing by 100-300mg every 1-7 days as tolerated, to mitigate withdrawal symptoms, as recommended by the Mayo Clinic 3, 6
  • Monitor for anxiety, insomnia, tremor, excessive sweating, tachycardia/palpitations, nausea/vomiting, headache, muscle aches, perceptual hypersensitivity, and tinnitus, and pause or slow the taper further if significant withdrawal symptoms emerge 3, 6

Non-Pharmacological Support

  • Cognitive-behavioral therapy during taper significantly increases success rates and should be incorporated if available, as recommended by the Mayo Clinic and the American Psychological Association 1, 2, 3, 6
  • Patient education about benzodiazepine risks and benefits of tapering improves outcomes, with the EMPOWER trial showing 62% of seniors expressed interest in changes after education 1, 2

Monitoring Requirements

  • Follow up at least monthly during the taper, with weekly contact during difficult phases, and monitor specifically for withdrawal symptoms, mood changes, suicidal ideation, and return of original condition symptoms, as recommended by the CDC and the American Academy of Family Physicians 3, 4, 6

Special Considerations

  • Re-evaluate whether diazepam is still providing benefit for the original condition and consider alternative treatments before or during the taper, as recommended by the Mayo Clinic and the American Academy of Family Physicians 1, 2, 4, 5
  • Elderly patients require more gradual tapers with smaller dose reductions, and the Beers criteria consider high-potency, long-acting, or prolonged benzodiazepine use as high risk in older adults, as recommended by the American Geriatrics Society 1, 2, 3

Critical Warnings

  • Warn the patient about increased overdose risk if returning to previous doses after tolerance is lost, and if the patient is taking opioids concurrently, taper the benzodiazepine first due to higher withdrawal risks, as recommended by the CDC and the American Academy of Family Physicians 3, 6
  • Pregnant patients should not taper without specialist consultation due to risks of spontaneous abortion and premature labor, as recommended by the American College of Obstetricians and Gynecologists 3

REFERENCES

3

Clonazepam Tapering Protocol [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

6

Managing Tinnitus from Benzodiazepine Withdrawal [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025